Extending the Special Exception to the NIH/AHRQ/NIOSH Post-Submission Material Policy During the COVID-19 Pandemic
Notice Number:
NOT-OD-20-163

Key Dates

Release Date:
August 12, 2020

Related Announcements

NOT-RM-21-004 - Notice of Clarification to the High-Risk, High-Reward Research Program: Pioneer: RFA-RM-20-011, New Innovator: RFA-RM-20-012, Transformative Research (RFA-RM-20-013, RFA-RM-20-020 & NOT-RM-20-019), and Early Independence (RFA-RM-20-014 & RFA-RM-20-021).

NOT-OD-20-179 - Extending the Special Exception to the NIH/AHRQ/NIOSH Post-Submission Material Policy During the COVID-19 Pandemic: August/October 2021 Councils.

NOT-EB-20-019 - Notice of Clarification to the NIBIB R21 Trailblazer Program (PAR-20-084).

NOT-OD-20-123 - Special Exception to the NIH/AHRQ/NIOSH Post-Submission Material Policy During the COVID-19 Pandemic

NOT-OD-19-083 - Update to the NIH/AHRQ/NIOSH Policy on Post-Submission Materials

Issued by

Office of The Director, National Institutes of Health (OD)

Purpose

This Notice extends the special exception for post-submission material (see NOT-OD-20-123) to applications submitted for the May 2021 Council round.

For applications submitted for the May 2021 council (beginning with applications submitted for the September 25, 2020 due date for Spring 2021 review meetings), the NIH, AHRQ, and NIOSH will accept a one-page update with preliminary data as post-submission materials for applications submitted under all activity codes, ONLY if the Funding Opportunity Announcement (FOA) used for submission allowed preliminary data in the application. One page of preliminary data will be accepted for single component applications or for each component of a multi-component application.

The deadline for submitting all post-submission materials, including preliminary data, will be 30 days before the study section meeting. Because applications for emergency competitive revisions and urgent competitive revisions undergo expedited review, post-submission materials will not be accepted for those applications.

All other materials listed in NOT-OD-19-083 as acceptable post-submission materials will continue to be accepted if submitted 30 days before the study section meeting.

Inquiries

Please direct all inquiries to:

Sally A. Amero, Ph.D.
NIH Review Policy Officer
ReviewPolicyOfficer@mail.nih.gov

Francis D. Chesley, Jr., M.D.
Agency for Healthcare Research and Quality
Telephone: 301-427-1521
Email: Francis.Chesley@ahrq.hhs.gov

Steve Dearwent, Ph.D.
Centers for Disease Control and Prevention
Telephone: 404-498-6382
Email: Sed7@cdc.gov

Michael Goldcamp, Ph.D.
Centers for Disease Control and Prevention
Telephone: 304-285-5951
Email: ehg8@cdc.gov


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices